#USA #Marlborough #Boston Scientific #FARAFLEX #TIVUS

Boston Scientific Commences 2025 with Remarkable Financial Performance

Boston Scientific Corporation (NYSE: BSX) has officially reported its financial results for the first quarter of 2025, showcasing impressive growth in both sales and profitability. The company recorded net sales amounting to $4.663 billion, reflecting a staggering 20.9% increase compared to the same quarter from the previous year. Notably, this substantial growth includes a 22.2% rise on an operational basis, and an 18.2% growth when adjusted for organic sales, outperforming initial guidance estimates.

Financial Highlights

In detail, Boston Scientific's GAAP net income attributable to common stockholders also made significant strides, reaching $674 million, which translates to $0.45 per share, up from $495 million or $0.33 per share in the prior year. Furthermore, the adjusted earnings per share (EPS) improved to $0.75, sharply higher than the $0.56 reported last year. These figures demonstrate the company's solid financial footing and operational efficiency.

According to Mike Mahoney, Chairman and CEO of Boston Scientific, the results underscore the diligence and commitment of the global team and the efficacy of their diverse product portfolio. He emphasized that the company is strategically positioned for continued success, focusing on innovative solutions and category leadership to ensure sustained growth.

Segment Performance and Regional Sales

Breaking down the financial performance further, sales growth was observed across several key segments:

• - MedSurg reported a growth of 11.7%, with operational growth at 12.8% and organic growth at 5.3%.
• - The Cardiovascular segment led the charge with a remarkable 26.2% reported increase; operational growth was 27.6%, while the organic segment grew by 25.6%.

Regionally, the United States alone accounted for 31.1% of the reported sales growth, while the broader EMEA region saw an increase of 5.5% and the Asia-Pacific recorded an 8.2% rise. Noteworthy too is the growing market presence in Latin America and Canada, which achieved a solid 4.4% operational growth.

Clinical Advances and Innovations

In addition to strong financial results, Boston Scientific is advancing its clinical research and innovation strategy. The company has initiated key clinical trials: the ELEVATE-PF trial aims to assess the FARAFLEX™ Mapping and Pulsed Field Ablation Catheter, while the OPTION-A trial will explore the combined use of the FARAPULSE™ PFA System with the WATCHMAN™ Left Atrial Appendage Closure Device in the Asia-Pacific region.

Additionally, the efficacy of the FARAPULSE™ PFA System was highlighted in published results from the SINGLE SHOT CHAMPION trial, where it was shown to outperform traditional cryoablation methods.

Moreover, Boston Scientific finalized its acquisition of Bolt Medical, Inc., which enriches its portfolio with advanced laser technology for treating vascular diseases. The company also announced plans to acquire SoniVie Ltd., enhancing its capabilities in treating hypertension via innovative intravascular ultrasound technology.

Looking Ahead

Looking forward, Boston Scientific anticipates continued growth in net sales for the full year of 2025, estimating a growth range of 15% to 17%. The company projects adjusted EPS for the year to fall between $2.87 to $2.94. Their estimates for net sales growth in the second quarter also align with robust performance targets, reflecting a sustained momentum across various segments and regions.

In conclusion, Boston Scientific's strong performance in Q1 2025 not only indicates a successful start to the year but also underscores its commitment to innovation and excellence in the medical technology field, aiming to improve patient care worldwide.